Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,173 questions in 89 reviews · Neuromuscular
current versionsNo studies 302 · 25.7%Ungraded 119 · 10.1%Very low 267 · 22.8%Low 239 · 20.4%Moderate 177 · 15.1%High 69 · 5.9%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Laser acupuncture vs placebo/sham laser acupuncture Overall clinical improvement at short‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | RR 1.59 [1.14, 2.22] | 1 study · 60 participants | Low |
Laser acupuncture vs placebo/sham laser acupuncture Overall clinical improvement at short‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | 1 study · 60 participants | Low |
Laser acupuncture vs placebo/sham laser acupuncture Overall clinical improvement at long‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | No studies |
Laser acupuncture vs placebo/sham laser acupuncture Adverse events (serious) · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | NR | Moderate |
Acupuncture vs oral corticosteroid Overall clinical improvement at short‐term · carpal tunnel syndrome Acupuncture and related interventions for the treatment of symptoms associated with carpal tunnel syndrome (2018) · Cochrane | no estimate extracted | 1 study · 77 participants | Very low |
Absorbable vs non‐absorbable sutures Postoperative pain: early pain (10 days postoperatively) VAS 0 to 10 Verbal reporting scale No pain‐mild pain‐moderate pain‐severe pain (converted to numerical scale (0 to 3, 3 to 6, 6 to 10) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | 3 studies · 137 participants | Very low |
Absorbable vs non‐absorbable sutures Wound Inflammation 6 to 12 weeks Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | RR 0.93 [0.06, 14.09] | 1 study · 54 participants | Very low |
Absorbable vs non‐absorbable sutures Postoperative scar satisfaction Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | RR 1.29 [0.97, 1.72] | NR | Very low |
Absorbable vs non‐absorbable sutures Adverse outcomes including wound infection, scar breakdown or return to theatre Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative pain: late pain (6 weeks postoperatively) VAS 0 to 10 Verbal reporting scale No pain‐mild pain‐moderate pain‐severe pain (converted to numerical scale (0 to 3, 3 to 6, 6 to 10) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | 4 studies · 175 participants | Very low |
Absorbable vs non‐absorbable sutures Postoperative hand function (2 weeks postoperatively) Mean CTS‐FSS score (scale 1 to 5, where higher scores indicate worse function) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | 1 study · 36 participants | Very low |
Absorbable vs non‐absorbable sutures Wound Inflammation 6 to 12 weeks Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | RR 2.28 [0.24, 21.91] | 2 studies · 95 participants | Very low |
Absorbable vs non‐absorbable sutures Postoperative scar satisfaction Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Adverse outcomes including wound infection, scar breakdown or return to theatre Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative pain: early pain (10 days postoperatively) VAS 0 to 10 Verbal reporting scale No pain‐mild pain‐moderate pain‐severe pain (converted to numerical scale (0 to 3, 3 to 6, 6 to 10) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | 1 study · 54 participants | Very low |
Absorbable vs non‐absorbable sutures Postoperative pain: late pain (6 weeks postoperatively) Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Absorbable vs non‐absorbable sutures Postoperative hand function Absorbable versus non‐absorbable sutures for skin closure after carpal tunnel decompression surgery (2018) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange vs sham exchange or supportive treatment Walking with aid at 4 weeks · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 1.6 [1.19, 2.15] | 3 studies · 349 participants | Moderate |
Plasma exchange vs sham exchange or supportive treatment Dependency on a ventilator at 4 weeks · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 0.53 [0.39, 0.74] | 5 studies · 623 participants | Moderate |
Plasma exchange vs sham exchange or supportive treatment Full muscle strength recovery at 1 year · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 1.24 [1.07, 1.45] | 5 studies · 404 participants | Moderate |
Plasma exchange vs sham exchange or supportive treatment Relapses at 1 year · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 2.89 [1.05, 7.93] | 6 studies · 649 participants | Moderate |
Plasma exchange vs sham exchange or supportive treatment Deaths at 1 year · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 0.86 [0.45, 1.65] | 6 studies · 649 participants | High |
Plasma exchange vs sham exchange or supportive treatment Severe infection · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | RR 0.91 [0.73, 1.13] | 3 studies · 556 participants | Moderate |
Plasma exchange vs sham exchange or supportive treatment 1Trials were not blinded. · people with Guillain‐Barré syndrome Plasma exchange for Guillain‐Barré syndrome (2017) · Cochrane | no estimate extracted | 1 participants | Ungraded |
Intervention NR Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | NR | No studies |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Change in impairment: change in grip strength at endpoint4 · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | 1 study · 38 participants | Moderate |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Sleeplessness · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 0.44 | 1 study · 40 participants | Low |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Moon facies · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 0.48 | 1 study · 40 participants | Moderate |
Intervention NR Change in impairment after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | 1 study · 28 participants | Very low |
Intervention NR Change in impairment after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Intervention NR Number of participants improved after 12 weeks (excluding those who did not complete the study) NIS score (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 2.4 | 1 study · 28 participants | Very low |
Intervention NR Number of participants improved after 12 weeks (including those who did not complete the study) NIS (range 0 to 280) · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 2.02 | 1 study · 35 participants | Very low |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Change in disability after one year · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | NR | No studies |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Remission at 12 months · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 1.11 | 1 study · 40 participants | Moderate |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone ≥ 1 point improvement on INCAT disability score at 12 months · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | RR 1.24 | 1 study · 40 participants | Low |
Monthly pulsed high‐dose dexamethasone vs oral prednisolone Change in impairment: change in MRC sum score at endpoint4 · people with chronic inflammatory demyelinating polyradiculoneuropathy Corticosteroids for chronic inflammatory demyelinating polyradiculoneuropathy (2017) · Cochrane | no estimate extracted | 1 study · 39 participants | Low |
Methotrexate vs placebo Participants able to reduce corticosteroid or IVIg dose by more than 20% · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | RR 1.21 [0.4, 3.7] | 1 study · 59 participants | Moderate |
Methotrexate vs placebo Change in disability after 26 or more weeks Overall Neuropathy Limitation Scale. Scale from: 0 to 12. · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | no estimate extracted | 1 study · 59 participants | Low |
Methotrexate vs placebo Change in disability after 26 or more weeks Amsterdam Linear Disability Scale. Scale from: 0 to 100. · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | no estimate extracted | 1 study · 59 participants | Low |
Methotrexate vs placebo Serious adverse events · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | RR 3.56 [0.39, 32.23] | 1 study · 59 participants | Moderate |
Interferon beta‐1a vs placebo Change in disability after 26 or more weeks · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Participants who completed the study and did not restart IVIg therapy after IVIg withdrawal · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | RR 1 [0.54, 1.88] | 1 study · 49 participants | Moderate |
Interferon beta‐1a vs placebo Serious adverse events · people with CIDP Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic… (2017) · Cochrane | RR 4.5 [0.25, 80.05] | 1 study · 67 participants | Low |
Tramadol vs placebo At least 30% reduction in pain · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | 2 studies · 157 participants | Low |
Tramadol vs placebo At least 50% reduction in pain · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | RR 2.2 [1.02, 4.6] | 3 studies · 265 participants | Low |
Tramadol vs placebo PGIC much or very much improved · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | 1 study · 35 participants | Very low |
Tramadol vs placebo Withdrawal due to adverse event · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | RR 4.1 [2, 8.4] | 6 studies · 485 participants | Low |
Tramadol vs placebo Participants experiencing any adverse event · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | RR 1.6 [1.2, 2.1] | 4 studies · 266 participants | Low |
Tramadol vs placebo Serious adverse events · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | NR | Very low |
Tramadol vs placebo Death · adults with neuropathic pain (any origin) Tramadol for neuropathic pain in adults (2017) · Cochrane | no estimate extracted | NR | Very low |